MoonLake Immunotherapeutics MLTX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $220.92M+8.9% | $202.86M+8.4% | $187.22M+15.3% | $162.32M+19.2% | $136.22M+20.8% | ||
| $267.37M+9.2% | $244.84M+6.8% | $229.2M+14.1% | $200.88M+17.6% | $170.76M+19.3% | ||
| $1.08M+76.8% | $611K+51.2% | $404K+6.0% | $381K+4.4% | $365K+29.4% | ||
| -$257.08M-13.1% | -$227.32M-8.0% | -$210.5M-19.5% | -$176.16M-21.3% | -$145.21M-22.1% | ||
| -$264.29M-9.1% | -$242.22M-6.7% | -$226.97M-14.0% | -$199.04M-17.6% | -$169.32M-19.5% | ||
| -$267.37M-9.2% | -$244.84M-6.8% | -$229.2M-14.1% | -$200.88M-17.6% | -$170.76M-19.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is MoonLake Immunotherapeutics profitable?
- MoonLake Immunotherapeutics is not currently profitable: it reported a net loss of $257.1M over the trailing twelve months.
- What is MoonLake Immunotherapeutics's earnings per share?
- MoonLake Immunotherapeutics's diluted EPS over the trailing twelve months is $-3.87.
- Where does MoonLake Immunotherapeutics's income statement data come from?
- Every line is extracted from MoonLake Immunotherapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.